The convergence of multi-omics and network pharmacology approaches could further augment the screening and identification of selective PXR modulators derived from traditional herbal compounds, thereby offering novel perspectives for the development of innovative therapeutic strategies targeting metabolic diseases. The gene discussed is NR1I2; the disease is metabolic disease.